Sangamo Therapeutics Inc.

Company Overview

Business Model: SANGAMO THERAPEUTICS, INC. is a genomic medicine company focused on neurological diseases. The company utilizes zinc finger epigenetic regulators and a capsid engineering platform to develop therapeutic candidates. Revenue generation primarily stems from collaboration agreements, including upfront license fees, milestone payments, and proceeds from common stock sales to collaborators, alongside potential future product sales from wholly-owned programs.

Market Position: The company operates in the highly competitive biotechnology and genomic medicine fields. Its proprietary technologies include the zinc finger (ZF) platform for epigenetic regulation (ZFNs, base editing, ZF-transcriptional regulators), the SIFTER platform for AAV capsid engineering, and the Modular Integrase (MINT) platform for protein-guided genome editing. A key differentiator is STAC-BBB, a proprietary engineered neurotropic AAV capsid variant that demonstrated 700-fold higher transgene expression than AAV9 in nonhuman primates, enabling robust transduction across the blood-brain barrier.

Recent Strategic Developments:

• Neurology Programs: The company's wholly-owned preclinical programs include idiopathic small fiber neuropathy (iSFN) and prion disease. For iSFN (ST-503), an IND was cleared by the FDA in November 2024, with Phase 1/2 study enrollment/dosing expected mid-2025 and preliminary proof of efficacy data anticipated in Q4 2026, subject to funding. For prion disease, a CTA submission in the U.K. is expected Q1 2026, with clinical trial enrollment/dosing mid-2026 and preliminary clinical data anticipated in Q4 2026, subject to funding. Collaboration partners Genentech, Inc., Alexion Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited are developing preclinical product candidates for tauopathies, amyotrophic lateral sclerosis (ALS), and Huntington’s disease.
• Other Clinical Programs: Isaralgagene civaparvovec (ST-920) for Fabry disease is in a Phase 1/2 STAAR clinical study, with FDA granting Orphan Drug, Fast Track, and RMAT designations, and EMA granting Orphan Medicinal Product designation and PRIME eligibility. The FDA agreed to an Accelerated Approval pathway using eGFR slope at 52 weeks, with complete 52-week eGFR slope data expected H1 2025 and potential BLA submission in H2 2025. Dosing was completed in April 2024 with 33 patients, and as of March 17, 2025, all 18 patients who started on enzyme replacement therapy (ERT) remain off ERT. Giroctocogene fitelparvovec (SB-525) for hemophilia A, co-developed with Pfizer Inc., achieved its primary objective in the Phase 3 AFFINE trial. However, Pfizer Inc. terminated the collaboration in December 2024, effective April 21, 2025, with SANGAMO THERAPEUTICS, INC. scheduled to regain development and commercialization rights and receive an exclusive, worldwide, royalty-bearing, sublicensable license from Pfizer Inc.
• Collaborations: In August 2024, SANGAMO THERAPEUTICS, INC. entered a global epigenetic regulation and capsid delivery license agreement with Genentech, Inc., receiving a $50.0 million upfront license fee and milestone payment, with eligibility for up to $1.9 billion in future milestones and tiered mid-single digit to sub-teen double digit royalties. In December 2024, a similar agreement with Astellas Gene Therapies, Inc. yielded a $20.0 million upfront payment, with eligibility for up to $1.3 billion in additional fees/milestones and tiered mid-to-high single digit royalties.
• Restructuring: The company undertook significant workforce reductions, including the wind-down of France R&D operations (93 roles eliminated, completed January 3, 2025), an April 2023 Restructuring (approximately 110 U.S. roles eliminated, completed Q3 2024), and a November 2023 Restructuring (approximately 162 U.S. roles eliminated, expected to be completed soon).

Geographic Footprint: The company's principal executive offices are in Richmond, California. As of December 31, 2024, it had 183 full-time employees globally, with 176 in the U.S. (primarily San Francisco Bay Area), 3 in Valbonne, France (operations wound down), and 4 in Germany and the U.K. Its corporate headquarters are in Richmond, California, and an additional facility in Brisbane, California, is expected to close soon. The Valbonne, France facility closed at the end of 2024. Clinical trials and regulatory activities span the U.S., Europe, and the U.K.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Operating Margin: -179.88% (2024)
• Net Margin: -169.45% (2024)

Investment in Growth:

• R&D Expenditure: $111,521 thousand (192.94% of revenue)
• Strategic Investments: Approximately $70.0 million in upfront license fees and milestone payments received from Genentech, Inc. and Astellas Gene Therapies, Inc. in 2024.

Capital Allocation Strategy

Shareholder Returns:

• No share repurchases or dividend payments were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $41.9 million (as of December 31, 2024)
• Total Debt: Not explicitly stated as a separate line item. Long-term portion of lease liabilities was $26.253 million (as of December 31, 2024).
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Operating leases have total future minimum payments of $37.0 million, with a weighted-average remaining lease term of 5.2 years and a weighted-average incremental borrowing rate of 7.7% as of December 31, 2024.

Cash Flow Generation:

• Operating Cash Flow: -$67,139 thousand (2024)
• Free Cash Flow: Not explicitly stated.

Operational Excellence

Production & Service Model: SANGAMO THERAPEUTICS, INC. is substantially reliant on external partners (CMOs) for the preclinical and clinical supply of its neurology portfolio. The company retains in-house analytical and process development capabilities. AAV vector production utilizes commercial scale insect-based baculovirus and clinical scale HEK293 mammalian platforms.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing-related supplier arrangements: Thermo Fisher Scientific Inc. - $2.9 million, expiring December 2025.
• CMOs: External partners for preclinical and clinical supply.

Facility Network:

• Manufacturing: Relies on CMOs.
• Research & Development: The company maintains approximately 59,485 square feet of research and office space at its Richmond, California headquarters. An additional facility in Brisbane, California, comprising approximately 103,089 square feet of office and R&D lab space, is expected to close soon. The Valbonne, France facility closed at the end of 2024.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels: The company's go-to-market strategy heavily involves strategic collaborations with major pharmaceutical companies for the development and potential commercialization of its pipeline assets. These partnerships include Genentech, Inc., Astellas Gene Therapies, Inc., Alexion Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Customer Portfolio: Strategic Partnerships:

• Genentech, Inc.: Global epigenetic regulation and capsid delivery license agreement.
• Astellas Gene Therapies, Inc.: Global epigenetic regulation and capsid delivery license agreement.
• Prevail Therapeutics Inc.: Research evaluation and option agreement for CSF-administered AAV capsids.
• nChroma Bio: Research evaluation, option and license agreement for epigenetic medicines leveraging ZFPs outside the CNS.
• Alexion Pharmaceuticals, Inc.: Collaboration and license agreement for ZF-transcriptional repressors to treat ALS and FTLD.
• Takeda Pharmaceutical Company Limited: Collaboration and license agreement for ZF therapeutics for Huntington’s Disease.
• Other Partnerships: Corteva AgriScience, Sigma-Aldrich Corporation, Open Monoclonal Technology, Inc. for plant agriculture and research reagents.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and genomic medicine fields are highly competitive and subject to extensive government regulation. Key regulatory bodies include the FDA, EMA, European Commission, EU Member States, and U.K. MHRA. Regulatory recommendations include a 15-year follow-up for gene therapy patients. Recent legislative changes such as the Inflation Reduction Act of 2022 (IRA) and the EU Clinical Trials Regulation (CTR) impact the industry's pricing and operational landscape.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Protein Pharmaceuticals: F. Hoffman-LaRoche Ltd., Protalix Biotherapeutics, Inc., Sanofi S.A.
• Gene Therapy: BioMarin Pharmaceutical, Inc., Spark Therapeutics, Spur Therapeutics Limited, Exegenesis Bio Co., 4D Molecular Therapeutics, Inc.
• CRISPR/Cas Gene Editing: Caribou Biosciences, Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Beam Therapeutics.
• Other Nuclease/Base Editing: Cellectis S.A. (TALE nucleases, meganucleases); bluebird bio, Inc. (Homing Endonucleases, MegaTALs); Precision BioSciences, Inc. (meganucleases).
• Antisense/RNA Interference: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Moderna, Inc., Regulus Therapeutics Inc., Voyager Therapeutics, Inc., Wave Life Sciences, Inc.
• Small Molecules: Biogen, Inc., Pfizer, Inc., Vertex Pharmaceuticals, Inc.
• AAV Capsid Technologies: 4D Molecular Therapeutics, Affinia Therapeutics Inc., Capsida Biotherapeutics, Dyno Therapeutics, Inc., StrideBio, Inc., Voyager Therapeutics, Inc.

Competitive Response Strategy: The company's strategy involves leveraging its proprietary zinc finger technology, advanced AAV capsid engineering platforms (SIFTER, STAC-BBB), and the MINT platform to develop novel genomic medicines. Strategic collaborations with larger pharmaceutical companies are crucial for funding, expertise, and broader market access, while also pursuing wholly-owned programs in high-need neurological diseases.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Competition: The highly competitive biotechnology and genomic medicine fields pose a risk, requiring continuous innovation and differentiation to maintain relevance.
• Technology Disruption: The rapid pace of scientific advancement in genomic medicine presents a risk of technological obsolescence from new or improved gene editing and delivery platforms.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Substantial reliance on external contract manufacturing organizations (CMOs) for preclinical and clinical supply introduces dependency risks.

Financial & Regulatory Risks

Market & Financial Risks:

• Credit & Liquidity: The company expects to meet liquidity requirements only into the middle of Q2 2025, raising substantial doubt about its ability to continue as a going concern for at least the next 12 months. Regulatory & Compliance Risks:
• Industry Regulation: The company operates in a heavily regulated environment, subject to stringent requirements from agencies such as the FDA, EMA, and U.K. MHRA.
• Regulatory Changes: New regulations, such as the Inflation Reduction Act of 2022 (IRA) impacting drug pricing and the EU Clinical Trials Regulation (CTR), can affect commercial viability and operational costs.
• Long-term Follow-up: FDA's recommendation for 15-year follow-up for gene therapy patients imposes long-term monitoring and associated costs.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Zinc finger (ZF) technology platform: This platform utilizes zinc finger proteins (ZFPs) for precise epigenetic regulation, including zinc finger nucleases (ZFNs) for gene disruption, base editing for specific DNA base conversions, and ZF-transcriptional regulators (ZFAs for activation, ZFRs for repression) for controlling gene expression.
• SIFTER platform: A proprietary AAV capsid engineering platform designed to improve central nervous system (CNS) transduction.
• Modular Integrase (MINT) platform: A protein-guided genome editing technology using Bxb1 serine recombinase to integrate large DNA sequences, designed to avoid double-stranded DNA breaks. Preclinical data demonstrated high on-target integration.
• STAC-BBB: An engineered neurotropic AAV capsid variant that has demonstrated the ability to cross the blood-brain barrier (BBB) in nonhuman primates, mediating robust transduction, transgene expression, and targeted epigenetic repression throughout the brain and spinal cord after intravenous administration. It showed 700-fold higher transgene expression than AAV9 in NHPs.

Innovation Pipeline:

• Wholly-owned preclinical programs: Idiopathic small fiber neuropathy (iSFN) (ST-503) and prion disease.
• Clinical programs: Isaralgagene civaparvovec (ST-920) for Fabry disease (Phase 1/2 STAAR study) and Giroctocogene fitelparvovec (SB-525) for hemophilia A (Phase 3 completed, rights reverting from Pfizer Inc.).
• Collaboration programs: Preclinical product candidates for tauopathies, ALS, and Huntington’s disease with Genentech, Inc., Alexion Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Intellectual Property Portfolio: SANGAMO THERAPEUTICS, INC. holds approximately 140 patent families. Issued patents for ZFP and ZFN design, engineered nucleases, and compositions have expected expiration dates ranging from 2029 to 2036. Nuclease Therapeutics patents are expected to expire between 2031 and 2036. One patent for Capsid Delivery Technologies (US11981967) has an expected expiration date in 2040.

Technology Partnerships:

• Strategic Alliances: Genentech, Inc., Astellas Gene Therapies, Inc., Prevail Therapeutics Inc., nChroma Bio, Alexion Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Corteva AgriScience, Sigma-Aldrich Corporation, Open Monoclonal Technology, Inc.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Alexander D. Macrae and Scott Willoughby are appointed as attorneys-in-fact and agents for signing amendments to the Annual Report on Form 10-K.

Board Composition: The Board of Directors includes H. Stewart Parker (Chair), Courtney Beers, Ph.D., Robert F. Carey, Kenneth J. Hillan, M.B., Ch.B., Margaret A. Horn, J.D., John H. Markels, Ph.D., James R. Meyers, and Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. The board's audit committee oversees cybersecurity risk management.

Human Capital Strategy

Workforce Composition:

• Total Employees: 183 full-time employees globally as of December 31, 2024.
• Geographic Distribution: 176 employees in the U.S. (primarily San Francisco Bay Area), 3 in Valbonne, France (operations wound down), and 4 in Germany and the U.K.
• Skill Mix: 83 employees are in Research & Development, 49 in technical operations/manufacturing, and 51 in general/administrative roles.

Talent Management: Acquisition & Retention:

• Employee Value Proposition: The company matched 401(k) contributions 100% up to $5,000 in both 2024 ($1.2 million contributed) and 2023 ($1.8 million contributed). All full-time employees globally receive equity ownership. U.S. employees have the option to purchase common stock at a ≥15% discount through an Employee Stock Purchase Plan (ESPP).

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Drug Development & Approval: The company's operations are subject to extensive regulation by the FDA in the U.S., the EMA and European Commission in the EU, EU Member States, and the U.K. MHRA.
• Long-term Follow-up: The FDA recommends a 15-year follow-up period for gene therapy patients, which impacts post-market surveillance and costs.
• Clinical Trials Regulation: The EU Clinical Trials Regulation (CTR) became applicable on January 31, 2022, standardizing clinical trial application and oversight processes across the EU.
• Health Technology Assessment: The EU HTA Regulation (No 2021/2282), adopted in December 2021, will apply iteratively from January 12, 2025, influencing market access and pricing decisions in Europe.

Legal Proceedings: SANGAMO THERAPEUTICS, INC. is not a party to any material pending legal proceeding.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company reported an income tax benefit of -$167 thousand in 2024 and -$5,072 thousand in 2023.
• Net Operating Loss Carryforwards: As of December 31, 2024, federal NOLs were $818.5 million (pre-2018 expire 2025-2037, post-2018 carry indefinitely), state NOLs were $349.8 million (expire beginning 2029), and French NOLs were $120.4 million (carry indefinitely).
• Research Tax Credit Carryforwards: As of December 31, 2024, federal research tax credits were $50.0 million (expire 2025-2043), and state research tax credits were $33.2 million (no expiration).

Insurance & Risk Transfer

Risk Management Framework: The company maintains information security processes and a cybersecurity risk management program. The board of directors' audit committee oversees cybersecurity risk management, with implementation and maintenance handled by management, including the Associate Director of IT and the VP of Finance & Corporate Controller.